Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.canlet.2014.03.010 http://scihub22266oqcxt.onion/10.1016/j.canlet.2014.03.010 C4366418!4366418!24657656     free     free     free       Cancer+Lett 2014 ; 348 (ä): 1-11 Nephropedia Template TP {{tp|p=24657656|t=2014. Prostaglandin E3 metabolism and cancer |pdf=|usr=}}{{24657656}} gab.com Text Prostaglandin E3 metabolism and cancer JO: Cancer Lett http://www.kidney.de/pget.php?&tw=1&pmid=24657656 #FOAvip The anticancer activity of n-3 fatty acids, especially those derived from fish, such as eicosapentaenoic acid (EPA) and docosahexaenoic acid) (DHA), has been studied for centuries. While there is a growing body of evidence that EPA and DHA may influence cancer initiation and development through targeting multiple events of tumor development, the underlying mechanisms responsible for these activities are still not fully understood. A number of studies have suggested that the anticancer activities of EPA and DHA are associated with their effects on eicosanoid metabolism by which they inhibit prostaglandin E2 (PGE2) production. In contrast to DHA, EPA can function as a substrate for cyclooxygenases (COXs) to synthesize unique 3-series prostaglandin compounds, especially PGE3. With advance technology in mass spectrometry, there is renewed interest in studying the role of PGE3 in EPA elicited anti-proliferative activity in various cancers, with some promising results. Here, we summarize the regulation of PGE3 synthesis in cancer cells and its role in EPA elicited anticancer activity. The development of PGE3 and its metabolites as potential biomarkers for future clinical evaluation of EPA and fish oil in cancer care is discussed. Twit Text FOAVip Prostaglandin E3 metabolism and cancer ????Cancer Lett http://www.kidney.de/pget.php?&tw=1&pmid=24657656 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24657656 #FOAvip English Wikipedia <ref>{{Cite pmid|24657656}}</ref> Prostaglandin E3 metabolism and cancer #MMPMID24657656 Yang P; Jiang Y; Fischer SM Cancer Lett 2014[Jun]; 348 (ä): 1-11 PMID24657656show ga The anticancer activity of n-3 fatty acids, especially those derived from fish, such as eicosapentaenoic acid (EPA) and docosahexaenoic acid) (DHA), has been studied for centuries. While there is a growing body of evidence that EPA and DHA may influence cancer initiation and development through targeting multiple events of tumor development, the underlying mechanisms responsible for these activities are still not fully understood. A number of studies have suggested that the anticancer activities of EPA and DHA are associated with their effects on eicosanoid metabolism by which they inhibit prostaglandin E2 (PGE2) production. In contrast to DHA, EPA can function as a substrate for cyclooxygenases (COXs) to synthesize unique 3-series prostaglandin compounds, especially PGE3. With advance technology in mass spectrometry, there is renewed interest in studying the role of PGE3 in EPA elicited anti-proliferative activity in various cancers, with some promising results. Here, we summarize the regulation of PGE3 synthesis in cancer cells and its role in EPA elicited anticancer activity. The development of PGE3 and its metabolites as potential biomarkers for future clinical evaluation of EPA and fish oil in cancer care is discussed. äProstaglandin E3 metabolism and cancer (epmc).pdf DeepDyve Pubget Overpricing